Opinion|Videos|October 11, 2024
Goals of Therapy and Considerations for Treatment Sequencing in Extensive Stage Small Cell Lung Cancer
Author(s)Ticiana Leal, MD
Ticiana Leal, MD, discusses how in cases of extensive stage small cell lung cancer (ES-SCLC) that progress within 6 months of platinum-based chemotherapy, treatment options such as tarlatamab, lurbinectedin, topotecan, and irinotecan should be considered, alongside the potential to extend chemoimmunotherapy cycles. She also addresses the impact of National Comprehensive Cancer Network (NCCN) guidelines and the consideration of prophylactic cranial irradiation (PCI) despite negative brain imaging results.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- In the case of ES-SCLC that progresses in less than 6 months after a second course of platinum-based chemotherapy, what other treatment options, in the absence of a clinical trial, would you consider as a subsequent line of therapy, and why?
- Would you alter your treatment sequencing for a similar case of ES-SCLC that had progressed after a CTFI longer than 6 months?
- How do the current NCCN clinical practice guidelines (V3.2024) inform your choice of preferred regimens?
- Despite negative results from serial brain MRI, would you consider PCI in this patient and why or why not?
Advertisement
Related to this article
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
The FDA recommended conducting a new trial showing an OS benefit with tovecimig in biliary cancer before submitting a BLA.
The NCCN Guidelines indicate rusfertide for patients regardless of risk status for patients who are intolerant to phlebotomy or receive frequent phlebotomy.
Community oncology practices rapidly adopt bispecific therapy, but reimbursement gaps, intensive monitoring demands, and limited hospital coordination hinder safe, scalable in-office programs.
Preview the 2026 International Myeloma Society meeting: the IMS/IMWG cure consensus, plenary session phase 3 trials, and new bispecific/CAR T myeloma findings.
During a roundtable event, Amit R. Mehta, MD, and participants discussed treatment selection for a patient with immune thrombocytopenia at risk of thrombotic events.
The FDA designation is for LYT-200 plus a hypomethylating agent for relapsed/refractory high-risk myelodysplastic syndromes.
Real-world ESAS data show higher symptom burden after cancer diagnosis shifts spending from treatment to ER, home and mental health care.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Evaluating Platelet- vs Immune-Directed Therapies in Immune Thrombocytopenia
2
What to Watch at IMS 2026: Defining Cure as Multitargeting, CELMoDs, and In Vivo CAR T Move Forward
3
Survey Reports Widespread Adoption of Bispecifics in Community Oncology
4
Rusfertide Receives NCCN Category 1 Designation in Polycythemia Vera
5